论文部分内容阅读
目的探讨达比加群酯在持续性心房颤动(房颤)接受导管射频消融术(RFCA)患者围手术期抗凝治疗中的安全性和有效性。方法将131例行RFCA的持续性房颤患者随机分为达比加群酯组(A组,58例)和华法林组(B组,73例),比较两组临床结局。结果两组患者术后均无死亡、大出血及血栓栓塞事件发生;A组缺血性脑病发生率与B组比较无统计学差异(3.45%vs.4.11%)(P>0.05);A组出血总发生率低于B组(3.45%vs.15.07%)(P<0.05)。结论达比加群酯可作为安全、稳定的持续性房颤患者RFCA围手术期的抗凝治疗药物。
Objective To investigate the safety and efficacy of dabigatran etexilate in perioperative anticoagulation in patients with persistent atrial fibrillation (AF) undergoing catheter radiofrequency catheter ablation (RFCA). Methods 131 patients with persistent AFCA who underwent RFCA were randomly assigned to receive either dabigatran etexilate (group A, n = 58) or warfarin (group B, n = 73). The clinical outcomes were compared between the two groups. Results No death, haemorrhage and thromboembolism occurred in both groups. There was no significant difference in the incidence of ischemic encephalopathy between group A and group B (3.45% vs 4..11%, P> 0.05) The overall incidence was lower than in group B (3.45% vs.15.07%) (P <0.05). Conclusion Dabigatran etexilate can be used as a perioperative anticoagulation therapy for RFCA in patients with persistent and stable AF.